Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Director Jack W. Schuler acquired 45,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 18th. The stock was bought at an average price of $20.14 per share, with a total value of $906,300.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Accelerate Diagnostics, Inc. (AXDX) traded down 0.50% during mid-day trading on Friday, reaching $19.85. The company had a trading volume of 376,677 shares. Accelerate Diagnostics, Inc. has a 12-month low of $18.35 and a 12-month high of $30.45. The firm has a 50-day moving average price of $22.12 and a 200 day moving average price of $25.32. The firm’s market capitalization is $1.10 billion.

Accelerate Diagnostics (NASDAQ:AXDX) last released its quarterly earnings data on Thursday, August 3rd. The medical research company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.01). Accelerate Diagnostics had a negative net margin of 5,062.48% and a negative return on equity of 67.44%. The firm had revenue of $0.70 million during the quarter, compared to analysts’ expectations of $1.40 million. Analysts expect that Accelerate Diagnostics, Inc. will post ($1.20) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This news story was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright and trademark laws. The correct version of this news story can be read at https://www.thecerbatgem.com/2017/10/21/accelerate-diagnostics-inc-axdx-director-jack-w-schuler-acquires-45000-shares-of-stock.html.

Hedge funds have recently added to or reduced their stakes in the business. Legal & General Group Plc increased its position in shares of Accelerate Diagnostics by 0.3% in the first quarter. Legal & General Group Plc now owns 5,123 shares of the medical research company’s stock valued at $123,000 after acquiring an additional 15 shares during the period. CLS Investments LLC purchased a new position in shares of Accelerate Diagnostics in the second quarter valued at about $137,000. SG Americas Securities LLC increased its position in shares of Accelerate Diagnostics by 16.8% in the first quarter. SG Americas Securities LLC now owns 5,885 shares of the medical research company’s stock valued at $142,000 after acquiring an additional 846 shares during the period. Quantbot Technologies LP purchased a new position in shares of Accelerate Diagnostics in the second quarter valued at about $228,000. Finally, UBS Asset Management Americas Inc. purchased a new position in shares of Accelerate Diagnostics in the second quarter valued at about $243,000. Hedge funds and other institutional investors own 44.43% of the company’s stock.

A number of analysts recently weighed in on AXDX shares. BidaskClub downgraded Accelerate Diagnostics from a “hold” rating to a “sell” rating in a report on Wednesday, August 9th. Zacks Investment Research downgraded Accelerate Diagnostics from a “buy” rating to a “hold” rating in a report on Tuesday, July 4th. BTIG Research restated a “buy” rating and issued a $34.00 price objective on shares of Accelerate Diagnostics in a report on Wednesday, July 12th. Finally, ValuEngine downgraded Accelerate Diagnostics from a “hold” rating to a “sell” rating in a report on Friday, August 11th. Three research analysts have rated the stock with a sell rating and two have issued a buy rating to the stock. Accelerate Diagnostics presently has a consensus rating of “Hold” and a consensus price target of $33.00.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic.

Insider Buying and Selling by Quarter for Accelerate Diagnostics (NASDAQ:AXDX)

Receive News & Stock Ratings for Accelerate Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics Inc. and related stocks with our FREE daily email newsletter.